NCT06367010Completed
Clinical Efficacy of 125I Brachytherapy Combined With Anlotinib in Radioiodine Refractory Thyroid Carcinoma Patients
Clinical Efficacy and Safety Analysis of 125I Brachytherapy Combined With Anlotinib in Radioiodine Refractory Thyroid Carcinoma Patients
Source: ClinicalTrials.gov · Last updated 16 Apr 2024
Brief summary (registry, in English)
A retrospective analysis was conducted on patients with radioiodine-refractory thyroid carcinoma (RRTC) who underwent radioactive 125I seed implantation combined with anlotinib from January 2019 to October 2024 at Jiangxi Cancer Hospital. Data on tumor size changes before and after treatment, serological tests (including serum TG, TgAb, CTn, CEA, etc.), changes in patients' pain scores, and side effects were collected to evaluate the clinical efficacy and safety of this therapy.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 8 (actual)
- First submitted
- 10 Apr 2024
- Start date
- 1 Jan 2019
- Primary completion date
- 1 Apr 2024
- Lead sponsor
- Jiangxi Provincial Cancer Hospital
- Diseases
- Thyroid cancer, Childhood cancers
- NCT number
- NCT06367010
What you commit to
- Study type: Observational
- Participants enrolled: 8
- From 1 Jan 2019 to the primary completion date, 1 Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- (v) Patients who are unable to cooperate with or tolerate particle implantation surgery;
Other illness
- (iii) Patients with severe coagulation disorders;
- (iv) Patients with severe cardiorespiratory impairment;
Other
- (i) Patients who are positive for TgAb;
- (ii) Patients with a TSH level of 0.1 mU/L or higher;
- (vi) Patients with an expected survival period of less than 3 months.
Who the study is looking for
- (i) Thyroid cancer confirmed through pathological examination;
- (ii) Disease progression after conventional treatments, such as surgery, postoperative 131I, and external irradiation;
- (iii) Multiple tumor foci, with at least one focus where the tumor's maximum diameter exceeds 3 cm.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Jiangxi Cancer Hospital Coordinator of this site? Confirm its status | Nanchang | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.